27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Appendix B. Coding tree of main categories and specific sub categories describing factors influencing readiness for advance care planning among people with dementia, family caregivers, and healthcare professionals. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Appendix A. Interview guides on experiences with advance care planning, factors influencing readiness for advance care planning, and the use of conversation aids among people with dementia, family caregivers, and healthcare professionals. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Evidence: low
Full summary, score breakdown and related studies → Original source
Individual biomarkers significantly predict decline across multiple cognitive domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma Aβ levels and regional WMH burden are associated with glymphatic dysfunction as indicated by reduced ALPS. 3 key findings →
Participants: 216 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Older adults with Alzheimer's disease (AD) frequently present to emergency departments (EDs) with multiple coexisting conditions. 5 key findings →
Design: cross-sectional Participants: 125,461 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Socioeconomic disadvantage is recognized as a risk factor for cognitive decline, yet its associated neural pathways remain unclear. 5 key findings →
Participants: 822 Evidence: low
Full summary, score breakdown and related studies → Original source
Anti-amyloid antibody treatment for Alzheimer’s disease is linked to Amyloid-Related Imaging Abnormalities (ARIA), including vasogenic edema (ARIA-E) and microhemorrhages (ARIA-H), especially in ApoE ε4/4 carriers. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Considering the overall sci-entific evidence presented, it is important to note that GLPs are no longer just antihyperglycemic drugs but are remarkably versatile, with a future in almost every field of medicine. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
DSI emerged as a significant predictor across both MoCA and CBB, surpassing the predictive power of both types of PTAs. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This case underscores the importance of routine sodium monitoring in elderly patients with dementia initiated on serotonergic or antipsychotic therapy. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study is one the first to account of attribute development for a DCE examining the public preferences for autonomy enhancing dementia care in Ireland. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The project Aging in Place applies a novel approach to investigate how social care services in Sweden are adapted to preferences and needs of older persons living at home with dementia (including their partners). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A persistent gap remains between policy ambitions and everyday practice. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This intervention represents the output of the iterative development of a complex intervention to fulfil an unmet need for PwD and sensory loss. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
From 1990 to 2021, global ADOD burden increased markedly in absolute terms. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Understanding regional and racial variation in the risk of hospitalization with Alzheimer's disease and related dementias (ADRD)-and how it differs from other conditions-is required to inform effective practice and policy. 2 key findings →
Participants: 143 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Concurrent diarrhea and wasting (DW) among children aged 6–24 months represents a critical public health threat in East Africa, exacerbating infection susceptibility, stunting, cognitive impairment, and mortality. 2 key findings →
Participants: 1,402 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Apoptosis, a programmed cell death process activated in Alzheimer disease (AD), is not limited to neurons but extends to all cell types within the central nervous system (CNS). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
LIUS was safe and demonstrated both cognitive improvement and reduced amyloid deposition in early‐stage AD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Neurodegeneration status was correctly identified in 78.8% (119/151) of amyloid-negative patients through visual rating, compared to 67.5% (102/151) using logistic regression. 5 key findings →
Participants: 379 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In older adults, temporal [18F]PI-2620 binding was higher in women (β = 0.543, P < 0.001) and APOE4 carriers (β = 0.395, P = 0.030) and was positively associated with plasma p-tau217 (β = 0.22, P = 0.008). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identity-by-descent (IBD) mapping provides complementary signals to genome-wide association studies (GWASs) when multiple causal haplotypes or variants are present but not directly tested. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We developed a serum Raman spectroscopy-based ensemble learning approach for graded cognitive screening. 5 key findings →
Participants: 220 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is a slow-growing neurological disorder that destroys human thought and consciousness. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →